Business
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Publication of Paper Entitled "Quality Assurance of Depression Ratings in Psychiatric Clinical Trials"
NRx-developed training and monitoring methodology in recently completed phase 2b/3 clinical trial of NRX-101 documents higher interrater reliability (IRR) on
About this update from Nrx Pharmaceuticals, Inc.
[{"type":"text","content":"NRx-developed training and monitoring methodology in recently completed phase 2b/3 clinical trial of NRX-101 documents higher interrater reliability (IRR) on primary endpoint (MADRS depression scale) than previously reported industry standardsPositive implications for conduct of future registration trials for NRX-101 and similar medications.Published in the peer reviewed American Journal of Clinical PsychopharmacologyWILMINGTON, Del., Nov. 25, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (\"NRx Pharmaceuticals\", the \"Company\"), a clinical-stage biopharmaceutical company, today announced the publication of a paper by Sapko, et. al. in the peer-reviewed American Journal of Clinical Psychopharmacology. The paper, entitled \"Quality Assurance of Depression Ratings in Psychiatric Clinical Trials,\"1 reported on the impact of a comprehensive program developed by NRx Pharmaceuticals to enhance reliability in psychometric ratings that are key to drug approval. Registration trials of drugs for depression and related conditions frequently fail because of unexpected statistical variability across study sites. NRx developed a methodology for training and monitoring the performance of the study site raters, whose measurements are key to the success or failure of all clinical trials of antidepressant drugs. This approach resulted in an unprecedented level of agreement (3 points or better on a 60 point scale) compared to prior industry practices.\n\n \n \n \n \n \n \n\n \n\"The rater training and monitoring methodology achieved by NRx's research team enabled the team to identify statistically significant improvements in recovery from suicidality and reduction in akathisia (a potentially lethal side effect of antidepressant drugs) with a compact study design of 90 patients. This methodology enabled statistical significance to be achieved with fewer than 100 participants, where typically several hundred would have been required,\" said Dr. Jonathan Javitt, Chairman, CEO and Chief Scientist of NRx Pharmaceuticals and senior author of the study. \"Clinical trials in antidepressant drugs rely on close coordination of human psychometric raters across study sites. Improving the reliability of this methodology increases our ability to bring new, lifesaving medicines to patients.\"\nIn the NRX-101 study, trial concordance, as define...